A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway

This publication has 34 references indexed in Scilit:

• Biochemical aspects of the inflammatory process: A narrative review
  Biomedicine & Pharmacotherapy, 2023
• Design, synthesis and anti-inflammatory activity study of lansiumamide analogues for treatment of acute lung injury
  Biomedicine & Pharmacotherapy, 2023
• Design, synthesis, and bioactivity evaluation of novel amide/sulfonamide derivatives as potential anti-inflammatory agents against acute lung injury and ulcerative colitis
  European Journal of Medicinal Chemistry, 2023
• Design, synthesis fusidic acid derivatives alleviate acute lung injury via inhibiting MAPK/NF-κB/NLRP3 pathway
  European Journal of Medicinal Chemistry, 2023
• Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases
  Biochemical Pharmacology, 2023
• Inhibition of Dyrk1A Attenuates LPS-Induced Neuroinflammation via the TLR4/NF-κB P65 Signaling Pathway
  Inflammation, 2022
• Recent research and development of DYRK1A inhibitors
  Chinese Chemical Letters, 2022
• Harmine is an inflammatory inhibitor through the suppression of NF-κB signaling
  Biochemical and Biophysical Research Communications, 2017
• Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries
  JAMA, 2016
• N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus
  Biochemical Pharmacology, 2010